Wockhardt gets US FDA nod to market Ceftazidime Injections

Ahmedabad, Oct 15 (UNI) Pharmaceutical major Wockhardt has received approval from the United States Food and Drug Administration (US FDA) for marketing the injections containing 1 Gm Vial Ceftazidime, which is used for treating various kinds of infections.

A company release said that ''Wockhardt is one of the only three companies to have received this approval.'' This product required significant R &D activity in both API and injections and is a reflection of the multi-faceted capabilities of Wockhardt to meet the challenges of the US markets.

Wockhardt's Ceftazidime injections will be launched in the US very shortly. According to IMS, the total market for Ceftazidime injections in the US is 42 million dollar, of which the 1 gm market has sales worth US dollar 12.6 million. 'Ceftazidime' is one of the most potent, powerful and safe antibiotics.

The Ceftazidime pentahydrate API is manufactured at Ankleshwar, Gujarat.

UNI PVN ZA SKB1827